Skip to main content
. 2020 Jan 29;15(1):e0228288. doi: 10.1371/journal.pone.0228288

Fig 3. Deterministic sensitivity analysis for the PD-L1-high model—pembrolizumab combination versus chemotherapy.

Fig 3

HR, hazard ratio; NSCLC, non-small cell lung cancer; ToT, time on treatment; OS, overall survival * Pembrolizumab combination therapy did not weakly dominate pembrolizumab monotherapy, therefore, the efficient frontier changed order and pembrolizumab combination no longer had an ICER compared to chemotherapy.